Cybin Inc. Common Stock (HELP)
Stock · NASDAQ · Health Care
$10.55as of 10/16/2026
Price chart
Active signals
HELP Signal Track Record
How signals performed across all stocks →What HELP's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 37 | -8.0% | 38% | September 17, 2026 |
| Bollinger Band Breakdown | 18 | -3.1% | 33% | October 6, 2026 |
| Bollinger Band Breakout | 17 | -0.8% | 47% | July 21, 2026 |
| 200-Day Moving Average TouchActive now | 10 | -7.9% | 40% | June 25, 2026 |
| Any 20-session window (baseline) | -5.1% | 40% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About HELP
Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders. The company…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 100
- Website
- www.helus.com
Fundamentals
- 1-day range
- $9.97$11.04
- Market cap
- $688.02M
- P/E (trailing)
- —
- P/E (forward)
- -5.90
- EPS (trailing)
- $-4.25
- Dividend yield
- —
- Beta
- 0.56
- Avg. volume
- 1.78M
Forecasts
10 analyst ratings
Cybin Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- HELPCybin Inc. Common Stock$10.55▼ 4.52%Market cap $688.02MP/E —$5.3$20.88
- EVOEvotec SE American Depositary Shares$1.38▼ 2.82%Market cap $693.72MP/E —$2.41$7.3
- NGNENeurogene Inc. Common Stock$23.25▼ 2.92%Market cap $680.52MP/E —$15.93$43.66
- PHATPhathom Pharmaceuticals Inc. Common Stock$6.92▼ 7.73%Market cap $678.76MP/E —$6.52$18.31
- IRWDIronwood Pharmaceuticals Inc. Class A Common Stock$3.5▼ 7.16%Market cap $701.25MP/E 4.68$1.41$5.78
- IMMXImmix Biopharma Inc. Common Stock$7.98▼ 8.06%Market cap $702.09MP/E —$2.31$15.1
- ZVRAZevra Therapeutics Inc. Common Stock$9.94▼ 3.21%Market cap $702.29MP/E 10.81$8.01$15.04
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| HELP Cybin Inc. Common Stock | $688.02M | — | $10.55 | ▼ 4.52% | $5.3$20.88 |
| EVO Evotec SE American Depositary Shares | $693.72M | — | $1.38 | ▼ 2.82% | $2.41$7.3 |
| NGNE Neurogene Inc. Common Stock | $680.52M | — | $23.25 | ▼ 2.92% | $15.93$43.66 |
| PHAT Phathom Pharmaceuticals Inc. Common Stock | $678.76M | — | $6.92 | ▼ 7.73% | $6.52$18.31 |
| IRWD Ironwood Pharmaceuticals Inc. Class A Common Stock | $701.25M | 4.68 | $3.5 | ▼ 7.16% | $1.41$5.78 |
| IMMX Immix Biopharma Inc. Common Stock | $702.09M | — | $7.98 | ▼ 8.06% | $2.31$15.1 |
| ZVRA Zevra Therapeutics Inc. Common Stock | $702.29M | 10.81 | $9.94 | ▼ 3.21% | $8.01$15.04 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Cybin (HELP) Stock May Be Trading At A Premium Despite Fresh Depression Trial DataYahoo · 9/25/2026
- Cybin (HELP) Shares Moved, What Is Behind The Fresh Attention?Yahoo · 9/24/2026
- Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major DepressionYahoo · 9/24/2026
- Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name ChangeYahoo · 9/22/2026
- Cybin Inc. To Officially Change Name To Helus Pharma Inc. Effective October 1, 2026Benzinga · 9/22/2026
- Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member BoardYahoo · 9/22/2026
- Cybin Inc. (HELP) Shareholder/Analyst Call Prepared Remarks TranscriptSeekingAlpha · 9/22/2026
- Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry SummitYahoo · 9/21/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 24.75M
- Total value held
- $117.87M
- Institutional holders
- 80
- Unknown3.85M
- Unknown3.83M
- Unknown2.42M
- Unknown1.54M
- Unknown1.53M
- Unknown1.41M
- Unknown1.31M
- Unknown1.03M
- Unknown987.1K
- Unknown915.6K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Cybin shareholders approve rebrand to Helus Pharma
Cybin shareholders recently approved a plan to change the company's name to Helus Pharma, effective October 1, 2026. This rebrand coincides with the company's focus on its HLP-003 drug for major depression, which is awaiting Phase III data. While the stock has seen fresh attention, analysts note it may be trading at a premium relative to its current valuation metrics.
Cybin shareholders approve rebrand to Helus Pharma. Cybin shareholders recently approved a plan to change the company's name to Helus Pharma, effective October 1, 2026. This rebrand coincides with the company's focus on its HLP-003 drug for major depression, which is awaiting Phase III data. While the stock has seen fresh attention, analysts note it may be trading at a premium relative to its current valuation metrics.